190 related articles for article (PubMed ID: 37848444)
21. Restoration of miR-340 controls pancreatic cancer cell
Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
[TBL] [Abstract][Full Text] [Related]
22. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
Front Immunol; 2022; 13():929339. PubMed ID: 36389667
[TBL] [Abstract][Full Text] [Related]
23. The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.
Peluso MO; Adam A; Armet CM; Zhang L; O'Connor RW; Lee BH; Lake AC; Normant E; Chappel SC; Hill JA; Palombella VJ; Holland PM; Paterson AM
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345627
[TBL] [Abstract][Full Text] [Related]
24. [Latest Findings on the Role of CD47 in Tumor Immune Evasion and Related Targeted Therapies].
Jie XL; Kong YY; Zhou GB
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):455-461. PubMed ID: 37248568
[TBL] [Abstract][Full Text] [Related]
25. CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early-stage prostate carcinoma.
Semiz HS; Küçük Ü; Kısa E; Keskinkılıç M; Süyün DE; Arayıcı ME; Atağ E; Karaoglu A
Prostate; 2022 Dec; 82(16):1564-1571. PubMed ID: 36031743
[TBL] [Abstract][Full Text] [Related]
26. CD47: role in the immune system and application to cancer therapy.
Hayat SMG; Bianconi V; Pirro M; Jaafari MR; Hatamipour M; Sahebkar A
Cell Oncol (Dordr); 2020 Feb; 43(1):19-30. PubMed ID: 31485984
[TBL] [Abstract][Full Text] [Related]
27. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
Front Immunol; 2020; 11():18. PubMed ID: 32082311
[TBL] [Abstract][Full Text] [Related]
28. Targeting CD47 Inhibits Tumor Development and Increases Phagocytosis in Oral Squamous Cell Carcinoma.
Ye XJ; Yang JG; Tan YQ; Chen XJ; Zhou G
Anticancer Agents Med Chem; 2021; 21(6):766-774. PubMed ID: 32748759
[TBL] [Abstract][Full Text] [Related]
29. Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy.
Zhu H; Leiss L; Yang N; Rygh CB; Mitra SS; Cheshier SH; Weissman IL; Huang B; Miletic H; Bjerkvig R; Enger PØ; Li X; Wang J
Oncotarget; 2017 Feb; 8(7):12145-12157. PubMed ID: 28076333
[TBL] [Abstract][Full Text] [Related]
30. Phagocytosis checkpoints as new targets for cancer immunotherapy.
Feng M; Jiang W; Kim BYS; Zhang CC; Fu YX; Weissman IL
Nat Rev Cancer; 2019 Oct; 19(10):568-586. PubMed ID: 31462760
[TBL] [Abstract][Full Text] [Related]
31. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
32. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
33. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F
J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808
[TBL] [Abstract][Full Text] [Related]
34. Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC.
Nigro A; Ricciardi L; Salvato I; Sabbatino F; Vitale M; Crescenzi MA; Montico B; Triggiani M; Pepe S; Stellato C; Casolaro V; Dal Col J
Front Immunol; 2019; 10():3135. PubMed ID: 32082304
[TBL] [Abstract][Full Text] [Related]
35. Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion.
Wang Z; Li B; Li S; Lin W; Wang Z; Wang S; Chen W; Shi W; Chen T; Zhou H; Yinwang E; Zhang W; Mou H; Chai X; Zhang J; Lu Z; Ye Z
Nat Commun; 2022 Oct; 13(1):6308. PubMed ID: 36274066
[TBL] [Abstract][Full Text] [Related]
36. PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro.
Martinez-Marin D; Jarvis C; Nelius T; de Riese W; Volpert OV; Filleur S
PLoS One; 2017; 12(4):e0174968. PubMed ID: 28403150
[TBL] [Abstract][Full Text] [Related]
37. Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.
He Y; Bouwstra R; Wiersma VR; de Jong M; Jan Lourens H; Fehrmann R; de Bruyn M; Ammatuna E; Huls G; van Meerten T; Bremer E
Nat Commun; 2019 Feb; 10(1):533. PubMed ID: 30710089
[TBL] [Abstract][Full Text] [Related]
38. Elimination of Cancer Cells in Co-Culture: Role of Different Nanocarriers in Regulation of CD47 and Calreticulin-Induced Phagocytosis.
Hassan EM; McWhirter S; Walker GC; Martinez-Rubi Y; Zou S
ACS Appl Mater Interfaces; 2023 Jan; 15(3):3791-3803. PubMed ID: 36632842
[TBL] [Abstract][Full Text] [Related]
39. Macrophages show higher levels of engulfment after disruption of
Hayes BH; Tsai RK; Dooling LJ; Kadu S; Lee JY; Pantano D; Rodriguez PL; Subramanian S; Shin JW; Discher DE
J Cell Sci; 2020 Mar; 133(5):. PubMed ID: 31964705
[TBL] [Abstract][Full Text] [Related]
40. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.
Weiskopf K; Jahchan NS; Schnorr PJ; Cristea S; Ring AM; Maute RL; Volkmer AK; Volkmer JP; Liu J; Lim JS; Yang D; Seitz G; Nguyen T; Wu D; Jude K; Guerston H; Barkal A; Trapani F; George J; Poirier JT; Gardner EE; Miles LA; de Stanchina E; Lofgren SM; Vogel H; Winslow MM; Dive C; Thomas RK; Rudin CM; van de Rijn M; Majeti R; Garcia KC; Weissman IL; Sage J
J Clin Invest; 2016 Jul; 126(7):2610-20. PubMed ID: 27294525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
